



MARKET RELEASE

5 March 2018

Noxopharm Limited

TRADING HALT

The securities of Noxopharm Limited (the “Company”) will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Wednesday, 7 March 2018 or when the announcement is released to the market.

Security Code: NOX

Cheng Tang
SENIOR ADVISER, LISTINGS COMPLIANCE (MELBOURNE)



ASX: NOX

Noxopharm Limited

ABN 50 608 966 123

**Registered Office
and**

Operational Office:

Suite 3, Level 4
828 Pacific Highway
Gordon NSW 2072
Australia

Board of Directors

Mr Peter Marks

Chairman
Non-Executive
Director

Dr Graham Kelly

Chief Executive Officer
Managing Director

Dr Ian Dixon

Non-Executive
Director

5th March 2018

Ms Cheng Tang
Adviser

Listings Compliance (Melbourne)
ASX Compliance Pty Limited
Level 4 Rialto North Tower
525 Collins Street
Melbourne VIC 3000

By Email: cheng.tang@asx.com.au

By Email: tradinghaltsmelbourne@asx.com.au

Dear Cheng,

NOXOPHARM LIMITED – TRADING HALT

The Company requests a trading halt effective immediately pending the presentation of clinical data by the Company to the Targeted Anti-Cancer Therapeutics conference in Paris on 5th March 2018.

The Company will be releasing this data to the market prior to market opening on 6th March 2018 at which time the trading halt will be lifted.

The Company is not aware of any reason why the trading halt should not be granted.

Thank you for your assistance. If you have any questions please contact the Company Secretary, David Franks on (02) 9299 9690.

For and on behalf of the Board,

Yours faithfully,

David Franks
Company Secretary